An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-01

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer

NCT03747783

Laryngeal Cancer

UNKNOWN

Transoral Laser Surgery and Radiotheraphy for Early Stage Laryngeal Squamous Cell Cancer

NCT04778306

Larynx Cancer

COMPLETED NA

Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer

NCT01089803

Squamous Cell Carcinoma Laryngeal Cancer

COMPLETED

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

NCT05900583

Minimal Residual Disease Esophageal Squamous Cell Carcinoma

UNKNOWN

CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1

NCT04455282

Cancer of Esophagus Esophagogastric Junction Disorder

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although there has been a significant increase in survival in many other cancer types through the years, no significant increase has been achieved in laryngeal SCC survival rates in the last 50 years. Despite the advancements in surgical techniques, organ preservation protocols and multidisciplinary approach, significant amount of patients have been living with morbidity or dying due to recurrence and metastasis. This lack of significant improvement in mortality rates creates the need for reliable and accurate biomarkers in early diagnosis, treatment and follow-up. Considering that the prognosis of two patients at the same clinical stage and treated with the same treatment protocol may differ, it suggests that there may be some differences at the molecular level apart from clinical stages.

This study was mainly prepared to determine serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin in patients with larynx squamous cell carcinoma; investigate their association with clinical parameters and determine their diagnostic and prognostic value.

To reach these aims, 60 patients who were prospectively and consecutively recruited from those who admitted to Hacettepe University, Department of Otorhinolaryngology, Ankara, Turkey, and were diagnosed with LSCC between May 2018 and February 2020. 20 healthy and age-matched controls were chosen from the hospital staff and relatives of the patients. Serum samples were obtained from all participants at the time of diagnosis, centrifuged and stored at -80 C. ELISA method will be used to analyze the serum levels of VEGF, sVEGFR1, VEGFR2, IGFBP-3, angiogenin and endoglin.

Data analysis will reveal if there are any association between biomarker candidate molecules and clinical parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Larynx Cancer Larynx Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

20 healthy age- and sex- matched controls

Obtaining blood samples

Intervention Type OTHER

Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.

Patient group

60 patients with laryngeal carcinoma

Obtaining blood samples

Intervention Type OTHER

Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obtaining blood samples

Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 60 male or female patients with a newly diagnosed laryngeal squamous cell carcinoma
* Patients without any previous history of laryngeal carcinoma
* 20 healthy, age- and sex- matched controls

Exclusion Criteria

* Previous history of laryngeal squamous cell carcinoma
* Having comorbid systemic diseases like DM, hypertension, cardiologic or rheumatologic diseases
* Having malign tumors elsewhere
* History of chemotherapy/radiotherapy.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes